What is HC Wainwright’s Estimate for TVTX FY2029 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for Travere Therapeutics in a note issued to investors on Wednesday, January 15th. HC Wainwright analyst E. Arce forecasts that the company will post earnings per share of $4.22 for the year. HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.92) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. The firm had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business’s revenue was up 69.6% compared to the same quarter last year. During the same period last year, the company earned ($1.17) earnings per share.

A number of other research firms have also recently commented on TVTX. Scotiabank lifted their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. Leerink Partners reiterated an “outperform” rating and set a $20.00 target price on shares of Travere Therapeutics in a research note on Tuesday, October 8th. Piper Sandler lifted their target price on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Finally, Citigroup decreased their price target on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, September 27th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Travere Therapeutics Stock Up 2.1 %

Shares of TVTX stock opened at $18.45 on Thursday. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $20.33. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -4.05 and a beta of 0.70. The firm’s 50-day moving average is $18.23 and its 200-day moving average is $14.37.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Aigen Investment Management LP bought a new position in shares of Travere Therapeutics during the 3rd quarter worth approximately $170,000. Oppenheimer & Co. Inc. acquired a new stake in Travere Therapeutics in the third quarter worth $673,000. Millennium Management LLC increased its stake in Travere Therapeutics by 33.9% in the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock valued at $24,244,000 after purchasing an additional 747,406 shares in the last quarter. FMR LLC boosted its position in shares of Travere Therapeutics by 27.5% during the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock worth $2,062,000 after purchasing an additional 31,772 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Travere Therapeutics by 18.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 264,816 shares of the company’s stock valued at $2,177,000 after buying an additional 41,048 shares during the period.

Insider Transactions at Travere Therapeutics

In related news, insider Jula Inrig sold 2,066 shares of Travere Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total transaction of $39,460.60. Following the completion of the transaction, the insider now owns 59,883 shares of the company’s stock, valued at $1,143,765.30. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Sandra Calvin sold 12,090 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $1,005,164.10. The trade was a 18.04 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,596 shares of company stock worth $527,262. Company insiders own 4.06% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.